New drugs for treating hypercholesterolemia and other hyperlipidaemias--the HMG CoA reductase inhibitors
Berger, G.M.; Marais, A.D.; Firth, J.C.
South African Medical Journal 77(2): 57-59
1990
ISSN/ISBN: 0256-9574 PMID: 2404345 Document Number: 366357
Document emailed within 1 workday
Related Documents
Hoeg, J.M.; Brewer, H.B. 1987: 3-Hydroxy-3-methylglutaryl--coenzyme a reductase inhibitors in the treatment of hypercholesterolemia JAMA 258(24): 3532-3536Pötsch, S.; Drechsler, H.; Liermann, B.; Gräslund, A.; Lassmann, G. 1994: P-Alkoxyphenols, a new class of inhibitors of mammalian R2 ribonucleotide reductase: possible candidates for antimelanotic drugs Molecular Pharmacology 45(4): 792-796
Giannini, S.D.; de Góes, J.M.; Dereviack, B.E.; Machado, C.; Forti, N.; Diament, J. 1990: Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis Arquivos Brasileiros de Cardiologia 54(6): 407-414
Wang, Z-jie.; Tian, X-zhi.; Li, X.; Chen, Z.; Zhao, L-cheng.; Zhou, B-fan.; Wu, Y-feng. 2005: Dietary treatment and success rate of control in hypercholesterolemia patients treated with lipid lowering drugs: a multi-center study of current status on clinical control of hypercholesterolemia in China Zhonghua Xin Xue Guan Bing Za Zhi 33(4): 372-375
Huddle, K.; Milne, F.J. 1991: Should ACE inhibitors be the drugs of choice in the treatment of hypertension in diabetes mellitus? ACE inhibitors are the drugs of choice in diabetic nephropathy South African Medical Journal 80(5): Suppl 10
Wilson, C.S. 1996: Treating hypercholesterolemia aggressively Nebraska Medical Journal 81(1): 3-4
Enjalbert, M.; Lussier-Cacan, S.; DuBreuil-Quidoz, S.; LeLorier, J.; Davignon, J. 1980: Usefulness of probucol in treating primary hypercholesterolemia Canadian Medical Association Journal 123(8): 754-757
Yamamoto, A. 2001: HMG-CoA reductase inhibitors Nihon Rinsho. Japanese Journal of Clinical Medicine 59(Suppl 3): 578-586
Davignon, J.; Montigny, M.; Dufour, R. 1992: HMG-CoA reductase inhibitors: a look back and a look ahead Canadian Journal of Cardiology 8(8): 843-864
Tomita, N.; Morishita, R.; Ogihara, T. 2002: Pharmacological effects of HMG-CoA reductase inhibitors Nihon Rinsho. Japanese Journal of Clinical Medicine 60(5): 955-961
Gmiński, J.; Wojakowski, W. 1997: Anti-atherosclerotic actions of HMG-CoA reductase inhibitors Przeglad Lekarski 54(11): 782-787
Erkelens, D.W.; Bravenboer, B. 1990: Aldose reductase inhibitors in diabetic neuropathy Nederlands Tijdschrift Voor Geneeskunde 134(15): 775-776
Fuentes, I.; Aguilera, C. 1998: Myopathy secondary to the treatment with inhibitors of HMG-CoA reductase Medicina Clinica 111(18): 700
Batzold, F.H. 1981: Approaches to prostatic 5 alpha-reductase inhibitors Progress in Clinical and Biological Research 75b: 269-282
Verburg, A.F.E.; van den Donk, M.; Wiersma, T. 2019: Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors Nederlands Tijdschrift Voor Geneeskunde 163
Klotz, L.H. 2006: Androgen replacement and/or 5 alpha reductase inhibitors in aging men Canadian Journal of Urology 13(Suppl 1): 44-45
Bagi, C.M. 2002: HMG-CoA reductase inhibitors - a review of the recent patent literature Idrugs: the Investigational Drugs Journal 5(3): 266-277
Bowden, K.; Harris, N.V.; Watson, C.A. 1993: Structure-activity relationships of dihydrofolate reductase inhibitors Journal of ChemoTherapy 5(6): 377-388
Cecha, J.ós.; Drabek, G.; Błazelonis, A.; Romanowski, W.; Zubelewicz-Szkodzińska, B. 2004: The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes Wiadomosci Lekarskie 57(5-6): 255-258
Azzouni, F.; Zeitouni, N.; Mohler, J. 2013: Role of 5α-reductase inhibitors in androgen-stimulated skin disorders Journal of Drugs in Dermatology: Jdd 12(2): E30-E35